Related Experiment Video
Updated: Jun 13, 2025
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
Published on: January 12, 2024
Proteolysis targeting chimera extracellular vesicles for therapeutic development treating triple negative breast
Abstract:
Proteolysis targeting chimeras (PROTACs) are an emerging targeted cancer therapy approach, but wide-spread clinical use of PROTAC is limited due to poor cell targeting and penetration, and instability in vivo. To overcome such issues and enhance the in vivo efficacy of PROTAC drugs, microfluidic droplet-based electroporation (µDES) was developed as a novel extracellular vesicle (EVs) transfection system, which enables the high-efficient PROTAC loading and effective delivery in vivo. Our previously developed YX968 PROTAC drug had shown the selectively degradation of HDAC3 and 8, which effectively suppresses the growth of breast tumor cell lines, including MDA-MB-231 triple negative breast cancer (TNBC) line, via dual degradation without provoking a global histone hyperacetylation. In this study, we demonstrated that µDES-based PROTAC loading in EVs significantly enhanced therapeutic function of PROTAC drug in vivo in the TNBC breast tumor mouse model. NSG mice with pre-established MDA-MB-231 tumors and treated with intraperitoneal injection of EVs for tumor inhibition study, which showed significantly higher HDAC 3 and 8 degradation efficiency and tumor inhibition than PROTAC only group. The liver, spleen, kidney, lung, heart, and brain were collected for safety testing, which exhibited improved toxicity. The EV delivery of PROTAC drug enhances drug stability and bioavailability in vivo, transportability, and drug targeting ability, which fills an important gap in current development of PROTAC therapeutic functionality in vivo and clinical translation. This novel EV-based drug transfection and delivery strategy could be applicable to various therapeutics for enhancing in vivo delivery, efficacy, and safety.
Insights
Extracellular vesicles (EVs) loaded with Proteolysis targeting chimeras (PROTACs) using microfluidic droplet-based electroporation (µDES) show enhanced in vivo breast cancer tumor inhibition and improved safety. This novel delivery system overcomes PROTAC limitations for better therapeutic efficacy.
Area of Science:
- Oncology
- Biotechnology
- Drug Delivery
Background:
- Proteolysis targeting chimeras (PROTACs) offer targeted cancer therapy but face challenges in clinical use due to poor delivery and in vivo stability.
- Existing PROTAC limitations hinder widespread application, necessitating innovative delivery strategies for enhanced therapeutic outcomes.
Purpose of the Study:
- To develop and evaluate a microfluidic droplet-based electroporation (µDES) system for loading PROTACs into extracellular vesicles (EVs) to improve in vivo delivery and efficacy.
- To assess the therapeutic potential of µDES-loaded PROTACs in a triple-negative breast cancer (TNBC) mouse model, focusing on tumor inhibition and safety.
Main Methods:
- Development of a novel microfluidic droplet-based electroporation (µDES) system for efficient PROTAC loading into EVs.
- In vivo efficacy study using NSG mice with MDA-MB-231 TNBC tumors, comparing intraperitoneal injection of EV-loaded PROTACs against PROTAC alone.
- Comprehensive safety assessment through analysis of major organs (liver, spleen, kidney, lung, heart, brain) for toxicity.
Main Results:
- µDES-based EV delivery significantly enhanced in vivo degradation of HDAC3 and 8 in TNBC tumors compared to PROTAC alone.
- A notable increase in tumor inhibition was observed in mice treated with EV-loaded PROTACs.
- Safety evaluations indicated improved toxicity profiles with the EV delivery system.
Conclusions:
- Microfluidic droplet-based electroporation (µDES) enables high-efficiency PROTAC loading into EVs, significantly enhancing in vivo therapeutic efficacy in TNBC models.
- EV delivery of PROTACs improves drug stability, bioavailability, transportability, and targeting, addressing key limitations for clinical translation.
- This EV-based drug transfection and delivery strategy holds promise for various therapeutics, improving in vivo delivery, efficacy, and safety.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
